Henry Brem is a Neurosurgery provider in Baltimore, Maryland. Dr. Brem is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Gliosarcoma, Glioma, Gliomatosis Cerebri, Osteotomy, and Posterior Fossa Decompression.

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Glioma, and Hepato-Pancreato-Biliary Surgery.

Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Glioma, Brain Tumor, Astrocytoma, and Glioblastoma.

David Kamson is an Oncologist in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Brain Tumor, Glioblastoma, Gliosarcoma, Metastatic Brain Tumor, and Hormone Replacement Therapy (HRT).

Dr. Debraj “Raj” Mukherjee’s clinical focus is the treatment of patients with primary and metastatic brain lesions. His clinical work and research emphasize the development of individual treatment plans that optimize survival and quality of life in all patients. After receiving his medical degree from Dartmouth Medical School, Dr. Mukherjee was recruited to Johns Hopkins, where he studied epidemiology, biostatistics and clinical design at the Johns Hopkins Bloomberg School of Public Health and served as Director of the Neuro-Oncology Surgical Outcomes Laboratory in the Department of Neurosurgery. Dr. Mukherjee completed neurosurgery residency at Cedars-Sinai Medical Center, where he was named a Robert Wood Johnson Foundation Health & Society Scholar. He completed an open and endoscopic skull base fellowship with the Center for Skull Base Surgery at University of Pittsburgh Medical Center, where he was a Copeland Scholar. Throughout his career, Dr. Mukherjee has led patient-centered research pursuits in neuro-oncology including development of a national registry for patients with brain tumors, creation of disease-specific quality of life instruments for patients with skull base tumors, and development of innovative clinical trials in neuro-oncology. He leads the Meningioma, Brain Metastasis, and Neurosurgical Oncology centers at Johns Hopkins Medicine, and he serves as Assistant Residency Program Director for one of the largest neurosurgical training programs in the country. His work has been supported by the American Medical Association, Glioblastoma Foundation, National Institute on Aging, and National Cancer Institute. Dr. Mukherjee can be contacted at drraj@jhmi.edu. Dr. Mukherjee is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Meningioma, Pituitary Tumor, Brain Tumor, Awake Craniotomy, and Craniectomy.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Brain Tumor, Chordoma, Astrocytoma, and Metastatic Brain Tumor.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Mark Goldstein is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Goldstein is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma.

John Laterra is a Neurologist in Baltimore, Maryland. Dr. Laterra is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Laterra is currently accepting new patients.

Mark Mishra is a Radiation Oncologist in Baltimore, Maryland. Dr. Mishra is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Metastatic Brain Tumor, Astrocytoma, Brain Tumor, Meningioma, and Prostatectomy. Dr. Mishra is currently accepting new patients.

Haroon Ahmad is a Neurologist in Baltimore, Maryland. Dr. Ahmad is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Oligodendroglioma, Glioma, Astrocytoma, and Glioblastoma.

Graeme Woodworth is a Neurosurgery provider in Baltimore, Maryland. Dr. Woodworth is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Woodworth is currently accepting new patients.

Samir Kanani is a Radiation Oncologist in Laurel, Maryland. Dr. Kanani is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET). Dr. Kanani is currently accepting new patients.

Tejan Diwanji is a Radiologist and a Radiation Oncologist in Halethorpe, Maryland. Dr. Diwanji is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, and Brain Tumor. Dr. Diwanji is currently accepting new patients.

Riaz Janjua is a Neurologist in Cumberland, Maryland. Dr. Janjua is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Memory Loss, Dravet Syndrome, Progressive Myoclonic Epilepsy, and Epilepsy. Dr. Janjua is currently accepting new patients.

Bassel Shneker is a Neurologist in Columbia, Maryland. Dr. Shneker is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Cervical Myelopathy, Hemangioblastoma, Dysembryoplastic Neuroepithelial Tumors (DNET), and Brain Stem Cancer.